Abstract
Purpose :
In diabetic macular edema (DME), en-face OCT presents two-dimensional distribution of microcysts, which intuitively indicates severity of the disease. In this study, utility of area measured by en-face OCT was examined comparing with the other factors in sectional OCT.
Methods :
17 eyes of 14 DME patients in our outpatient clinic (Tokyo Medical and Dental University Hospital), who were given anti-VEGF therapy (either Ranibizumab or Aflibercept) and en-face OCT examination (RTVueXR Avanti®) from March 2015 to November 2015, were included. Data obtained from clinical records and OCT images were retrospectively examined. The area of DME was measured by en-face OCT (3mm square). The central or maximum retinal thickness was measured by sectional swept-source OCT (Topcon Atlantis®). Correlation analysis was performed within the areas of macular edema, central retinal thickness and maximum retinal thickness.
Results :
The area of DME measured by en-face OCT was significantly correlated with central retinal thickness by sectional OCT (p<0.0001). When comparing before and after administrations of the anti VEGF drugs, the alteration of area and that of maximum retinal thickness were significantly related (p=0.011). In this study, the comparison between the Ranibizumab treated and the Aflibercept treated group showed no significant differences in those factors.
Conclusions :
En-face OCT is useful for clinical management of DME not only it give us intuitive two-dimensional pathology but also it is related to other conventional factors in sectional OCT. Utilizing en-face OCT in the assessment of therapeutic effects is also hopeful.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.